Oseltamivir(196618-13-0)

Anti-influenza drug: oseltamivir phosphate is an anti-influenza drug of neuraminidase inhibitor, marketed in 1999, with the trade name Tamiflu (Tamiflu, also known as "Tamiflu"). It was first discovered by Gilead Sciences, then jointly developed with Roche and approved for listing in the United States. Oseltamivir phosphate is the first oral effective neuraminidase inhibitor, which is effective against influenza A and B viruses. After oral oseltamivir is rapidly converted into its active metabolite oseltamivir carboxylic acid by liver and intestinal esterase. The configuration of oseltamivir carboxylic acid is similar to the transition state of neuraminic acid, which can competitively combine with the active site of influenza virus neuraminidase (NA). Therefore, oseltamivir is a powerful and highly selective influenza virus NA inhibitor (NAIs), which is mainly released from infected host cells by interfering with the virus, So as to reduce the transmission of influenza A or B virus. Therefore, oseltamivir phosphate is a precursor drug. At present, oseltamivir phosphate (Tamiflu) is still recognized as one of the most effective drugs for the treatment of influenza A (H1N1) among the drugs already on the market. It was approved for marketing in China in July 2004.